176 related articles for article (PubMed ID: 32891378)
1. A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes.
Wang X; Deng L; Gjertsen BT
Anal Chim Acta; 2020 Sep; 1129():1-11. PubMed ID: 32891378
[TBL] [Abstract][Full Text] [Related]
2. Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device.
Yin C; Wang Y; Ji J; Cai B; Chen H; Yang Z; Wang K; Luo C; Zhang W; Yuan C; Wang F
Anal Chem; 2018 Mar; 90(6):3744-3751. PubMed ID: 29464943
[TBL] [Abstract][Full Text] [Related]
3. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
4. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-cocktail Functionalized Nano-microfluidic Chip for Enhancing Isolation and Characterization of Circulating Cancer Cells.
Li M; Liu D; Zhang J; Zhang X; Dou X
Anticancer Res; 2022 Sep; 42(9):4345-4358. PubMed ID: 36039433
[TBL] [Abstract][Full Text] [Related]
8. Discriminating Epithelial to Mesenchymal Transition Phenotypes in Circulating Tumor Cells Isolated from Advanced Gastrointestinal Cancer Patients.
Carneiro A; Piairo P; Teixeira A; Ferreira D; Cotton S; Rodrigues C; Chícharo A; Abalde-Cela S; Santos LL; Lima L; Diéguez L
Cells; 2022 Jan; 11(3):. PubMed ID: 35159186
[TBL] [Abstract][Full Text] [Related]
9. Combination of antibody-coated, physical-based microfluidic chip with wave-shaped arrays for isolating circulating tumor cells.
Chen H; Cao B; Chen H; Lin YS; Zhang J
Biomed Microdevices; 2017 Sep; 19(3):66. PubMed ID: 28776234
[TBL] [Abstract][Full Text] [Related]
10. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
12. A microchip filter device incorporating slit arrays and 3-D flow for detection of circulating tumor cells using CAV1-EpCAM conjugated microbeads.
Kim YJ; Koo GB; Lee JY; Moon HS; Kim DG; Lee DG; Lee JY; Oh JH; Park JM; Kim MS; Woo HG; Kim SI; Kang P; Choi W; Sim TS; Park WY; Lee JG; Kim YS
Biomaterials; 2014 Aug; 35(26):7501-10. PubMed ID: 24917030
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition.
Lowes LE; Allan AL
Adv Clin Chem; 2018; 83():121-181. PubMed ID: 29304900
[TBL] [Abstract][Full Text] [Related]
14. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
16. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
Chebouti I; Kasimir-Bauer S; Buderath P; Wimberger P; Hauch S; Kimmig R; Kuhlmann JD
Oncotarget; 2017 Jul; 8(30):48820-48831. PubMed ID: 28415744
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma.
Sun YF; Guo W; Xu Y; Shi YH; Gong ZJ; Ji Y; Du M; Zhang X; Hu B; Huang A; Chen GG; Lai PBS; Cao Y; Qiu SJ; Zhou J; Yang XR; Fan J
Clin Cancer Res; 2018 Feb; 24(3):547-559. PubMed ID: 29070526
[No Abstract] [Full Text] [Related]
18. anti-EGFR capture mitigates EMT- and chemoresistance-associated heterogeneity in a resistance-profiling CTC platform.
Thege FI; Gruber CN; Cardle II; Cong SH; Lannin TB; Kirby BJ
Anal Biochem; 2019 Jul; 577():26-33. PubMed ID: 30790546
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]